Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease

Parkinson’s disease (PD) is characterized by progressive neurodegeneration of dopaminergic neurons in the ventral midbrain. The complement-phagosome pathway is involved in the pathogenesis of PD. Here we measured levels of complement-phagocytosis molecules, including galectin-3, C3, C4, and cathepsi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hsiu-Chuan Wu, Kuo-Hsuan Chang, Mu-Chun Chiang, Chiung-Mei Chen
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	Parkinson’s disease complement phagocytosis galectin-3 C3 biomarker Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/3c805b253b234da5ba17f579a322b431
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3c805b253b234da5ba17f579a322b431
record_format	dspace
spelling	oai:doaj.org-article:3c805b253b234da5ba17f579a322b4312021-11-25T16:58:50ZAlterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease10.3390/brainsci111115152076-3425https://doaj.org/article/3c805b253b234da5ba17f579a322b4312021-11-01T00:00:00Zhttps://www.mdpi.com/2076-3425/11/11/1515https://doaj.org/toc/2076-3425Parkinson’s disease (PD) is characterized by progressive neurodegeneration of dopaminergic neurons in the ventral midbrain. The complement-phagosome pathway is involved in the pathogenesis of PD. Here we measured levels of complement-phagocytosis molecules, including galectin-3, C3, C4, and cathepsin D, in the plasma of 56 patients with PD, and 46 normal controls (NCs). Plasma levels of galectin-3 (9.93 ± 3.94 ng/mL) were significantly higher in PD patients compared with NCs (8.39 ± 1.95 ng/mL, <i>p</i> = 0.012), and demonstrated a positive correlation with Hoehn and Yahr stages in PD patients (R<sup>2</sup> = 0.218, <i>p</i> < 0.001). On the other hand, plasma C3 levels were significantly lower in PD patients (305.27 ± 205.16 μg/mL) compared with NCs (444.34 ± 245.54 μg/mL, <i>p</i> = 0.002). However, the levels did not correlate with Hoehn and Yahr stages (R<sup>2</sup> = 0.010, <i>p</i> = 0.469). Plasma levels of C4 and cathepsin D in PD patients were similar to those in NCs. Our results show possible altered complement-phagocytosis signals in the peripheral blood of PD patients, highlighting the potential of galectin-3 as a biomarker of PD.Hsiu-Chuan WuKuo-Hsuan ChangMu-Chun ChiangChiung-Mei ChenMDPI AGarticleParkinson’s diseasecomplementphagocytosisgalectin-3C3biomarkerNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBrain Sciences, Vol 11, Iss 1515, p 1515 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Parkinson’s disease complement phagocytosis galectin-3 C3 biomarker Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	Parkinson’s disease complement phagocytosis galectin-3 C3 biomarker Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Hsiu-Chuan Wu Kuo-Hsuan Chang Mu-Chun Chiang Chiung-Mei Chen Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease
description	Parkinson’s disease (PD) is characterized by progressive neurodegeneration of dopaminergic neurons in the ventral midbrain. The complement-phagosome pathway is involved in the pathogenesis of PD. Here we measured levels of complement-phagocytosis molecules, including galectin-3, C3, C4, and cathepsin D, in the plasma of 56 patients with PD, and 46 normal controls (NCs). Plasma levels of galectin-3 (9.93 ± 3.94 ng/mL) were significantly higher in PD patients compared with NCs (8.39 ± 1.95 ng/mL, <i>p</i> = 0.012), and demonstrated a positive correlation with Hoehn and Yahr stages in PD patients (R<sup>2</sup> = 0.218, <i>p</i> < 0.001). On the other hand, plasma C3 levels were significantly lower in PD patients (305.27 ± 205.16 μg/mL) compared with NCs (444.34 ± 245.54 μg/mL, <i>p</i> = 0.002). However, the levels did not correlate with Hoehn and Yahr stages (R<sup>2</sup> = 0.010, <i>p</i> = 0.469). Plasma levels of C4 and cathepsin D in PD patients were similar to those in NCs. Our results show possible altered complement-phagocytosis signals in the peripheral blood of PD patients, highlighting the potential of galectin-3 as a biomarker of PD.
format	article
author	Hsiu-Chuan Wu Kuo-Hsuan Chang Mu-Chun Chiang Chiung-Mei Chen
author_facet	Hsiu-Chuan Wu Kuo-Hsuan Chang Mu-Chun Chiang Chiung-Mei Chen
author_sort	Hsiu-Chuan Wu
title	Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease
title_short	Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease
title_full	Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease
title_fullStr	Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease
title_full_unstemmed	Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease
title_sort	alterations of plasma galectin-3 and c3 levels in patients with parkinson’s disease
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/3c805b253b234da5ba17f579a322b431
work_keys_str_mv	AT hsiuchuanwu alterationsofplasmagalectin3andc3levelsinpatientswithparkinsonsdisease AT kuohsuanchang alterationsofplasmagalectin3andc3levelsinpatientswithparkinsonsdisease AT muchunchiang alterationsofplasmagalectin3andc3levelsinpatientswithparkinsonsdisease AT chiungmeichen alterationsofplasmagalectin3andc3levelsinpatientswithparkinsonsdisease
_version_	1718412832248168448

Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease

Ejemplares similares